#1 Clinical Trials Search in Europe

Pozelimab

Pozelimab is an experimental drug being studied in clinical trials for the treatment of several rare diseases, including CD55-deficient protein-losing enteropathy (CHAPLE disease) and paroxysmal nocturnal hemoglobinuria (PNH). This article explores the ongoing research into Pozelimab’s safety, efficacy, and potential benefits for patients with these challenging conditions.

Table of Contents

What is Pozelimab?

Pozelimab, also known by its experimental name REGN3918, is a new drug being developed to treat certain rare blood disorders[1]. It is a type of medicine called a monoclonal antibody, which means it’s a laboratory-made protein designed to target specific parts of the immune system[2].

This drug works by targeting a part of the immune system called the complement system. Specifically, it blocks a protein called C5, which is involved in a process that can lead to the destruction of red blood cells in certain diseases[4].

What Conditions Does Pozelimab Treat?

Pozelimab is being studied for the treatment of several rare conditions:

  • CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease): This is a rare inherited disease of the immune system that usually affects children. It can be life-threatening and causes problems with the digestive system, leading to loss of important proteins from the body[1].
  • Paroxysmal Nocturnal Hemoglobinuria (PNH): This is a rare blood disorder where red blood cells break down faster than they should. This can lead to various symptoms including fatigue, difficulty breathing, and an increased risk of blood clots[4].
  • Generalized Myasthenia Gravis (gMG): This is a chronic autoimmune disorder that causes muscle weakness and fatigue. It occurs when there’s a breakdown in the normal communication between nerves and muscles[5].

How is Pozelimab Administered?

Pozelimab is typically given as a subcutaneous (SC) injection, which means it’s injected just under the skin[1]. In some cases, it may be given intravenously (IV), which means it’s injected directly into a vein[8]. The exact dosing and frequency of administration can vary depending on the condition being treated and the specific clinical trial protocol.

Current Clinical Trials

Pozelimab is currently being studied in several clinical trials:

  • A study for patients with CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)[2]
  • Studies for patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)[4][6]
  • A study for patients with Generalized Myasthenia Gravis (gMG)[5]
  • Studies in healthy volunteers to understand how the drug works in the body[7][8]

These trials are designed to test how safe and effective pozelimab is, how it affects various symptoms and lab tests, and how it impacts patients’ quality of life.

Combination Therapy with Cemdisiran

In some clinical trials, pozelimab is being studied in combination with another drug called cemdisiran (also known as ALN-CC5)[4][6]. Cemdisiran works differently from pozelimab but targets the same part of the immune system. The combination of these two drugs is being tested to see if it provides better results than either drug alone.

Safety and Side Effects

As with all new medications, researchers are closely monitoring the safety of pozelimab. The clinical trials are designed to identify any side effects or adverse events that may occur. Common ways of assessing safety include:

  • Monitoring for treatment-emergent adverse events (TEAEs), which are any new medical problems that occur or worsen after starting the treatment[2]
  • Checking for the development of anti-drug antibodies (ADAs), which are antibodies that the body might produce against the drug[4]
  • Regular blood tests and physical examinations

It’s important to note that as pozelimab is still in clinical trials, not all potential side effects may be known yet. Patients in clinical trials are closely monitored by healthcare professionals.

Future Prospects

Pozelimab shows promise in treating several rare and serious conditions. If the clinical trials are successful, it could provide a new treatment option for patients who may have limited choices currently. However, it’s important to remember that drug development is a long process, and more research is needed before pozelimab could become widely available.

For patients interested in learning more about pozelimab or potentially participating in a clinical trial, it’s best to discuss this with your healthcare provider. They can provide more information and help determine if a clinical trial might be appropriate for your specific situation.

Aspect Details
Drug Name Pozelimab (also known as REGN3918)
Drug Type Human monoclonal antibody
Conditions Studied CD55-deficient protein-losing enteropathy (CHAPLE disease), Paroxysmal nocturnal hemoglobinuria (PNH), Generalized myasthenia gravis
Administration Methods Subcutaneous injection, Intravenous infusion
Combination Therapy Studied in combination with Cemdisiran in some trials
Primary Study Objectives Safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics
Key Outcome Measures Adverse events, changes in disease markers (e.g., LDH levels), quality of life assessments, hemoglobin levels, transfusion requirements
Study Populations Adults with specific rare diseases, healthy volunteers (including Japanese participants in some studies)
Trial Phases Various (including early-phase and compassionate use studies)

FAQ

  • What is Pozelimab? Pozelimab is an experimental drug being studied for the treatment of rare diseases. It is a human monoclonal antibody that targets specific components of the immune system.
  • What conditions is Pozelimab being studied for? Pozelimab is being investigated for CD55-deficient protein-losing enteropathy (CHAPLE disease), paroxysmal nocturnal hemoglobinuria (PNH), and generalized myasthenia gravis.
  • How is Pozelimab administered? Pozelimab is typically administered through subcutaneous (under the skin) injection. Some studies also explore intravenous (into a vein) administration.
  • What are the main goals of the Pozelimab clinical trials? The main goals are to evaluate the safety, tolerability, and effectiveness of Pozelimab in treating specific rare diseases. Researchers are also studying how the drug works in the body and its effects on disease symptoms and quality of life.
  • Is Pozelimab being studied in combination with other drugs? Yes, several trials are investigating Pozelimab in combination with another drug called Cemdisiran for conditions like PNH and generalized myasthenia gravis.

Ongoing Clinical Trials on Pozelimab

  • Study of Pozelimab and Cemdisiran for Adults with Geographic Atrophy from Age-Related Macular Degeneration

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria France Germany Hungary Italy Poland +1

  • Long-term safety and effectiveness study of pozelimab and cemdisiran combination treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH)

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Greece Hungary Italy Poland Romania Spain

  • Study of Pozelimab and Cemdisiran in Adults with Paroxysmal Nocturnal Hemoglobinuria Not Responding Well to Current C5 Inhibitor Treatment

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Poland Spain

  • Study on the Safety and Effectiveness of Pozelimab and Cemdisiran for Adults with Paroxysmal Nocturnal Hemoglobinuria Not Recently Treated with Complement Inhibitors

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Greece Hungary Italy Poland Romania Spain

Glossary

  • CD55-deficient protein-losing enteropathy (CHAPLE disease): A rare inherited disease of the immune system that can cause life-threatening protein loss through the intestines, usually diagnosed in childhood.
  • Paroxysmal nocturnal hemoglobinuria (PNH): A rare blood disorder characterized by the destruction of red blood cells, blood clots, and impaired bone marrow function.
  • Generalized myasthenia gravis: An autoimmune disorder causing muscle weakness and fatigue due to impaired communication between nerves and muscles.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to specific targets in the body, used in the treatment of various diseases.
  • Subcutaneous injection: A method of administering medication by injecting it into the layer of tissue between the skin and muscle.
  • Intravenous administration: Delivering medication directly into a vein using a needle or tube.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and relationship between drug concentration and effect.
  • Lactate dehydrogenase (LDH): An enzyme found in many body tissues, often used as a marker of cell damage or disease activity.
  • Hemolysis: The destruction or breakdown of red blood cells, which can lead to anemia and other health problems.

References

  1. https://clinicaltrials.gov/study/NCT06003881
  2. https://clinicaltrials.gov/study/NCT04209634
  3. https://clinicaltrials.gov/study/NCT04491838
  4. https://clinicaltrials.gov/study/NCT04811716
  5. https://clinicaltrials.gov/study/NCT05070858
  6. https://clinicaltrials.gov/study/NCT04888507
  7. https://clinicaltrials.gov/study/NCT04601844
  8. https://clinicaltrials.gov/study/NCT04940364